DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinomaAllison M. Kirk, Paul G. Thomas, Phuong Nguyen et al.|Cell Reports Medicine|2024Cited by 15
Abstract 1383: Characterization of CD8 T cell responses to <i>DNAJB1-PRKACA</i> fusion neoantigens in fibrolamellar carcinomaAllison M. Kirk, Paul G. Thomas, Ching‐Heng Chou et al.|Cancer Research|2022Cited by 1
348 Defining T cell recognition of a highly conserved fusion neoantigen in fibrolamellar carcinomaAllison M. Kirk, Paul Thomas, Jeremy Chase Crawford et al.|Regular and Young Investigator Award Abstracts|2022Cited by 0
CD8 T cell responses to conserved <i>DNAJB1-PRKACA</i> fusion neoantigens in fibrolamellar carcinomaAllison M. Kirk, Paul G. Thomas, Ching‐Heng Chou et al.|The Journal of Immunology|2022Cited by 0